Cspc Zhongqi Pharmaceutical Technology Co., Ltd.
Clinical trials sponsored by Cspc Zhongqi Pharmaceutical Technology Co., Ltd., explained in plain language.
-
New combo therapy aims to stall rare gut tumors
Disease control Recruiting nowThis study tests whether adding a targeted drug (sirolimus) to a standard hormone-blocking injection (octreotide) can better control advanced neuroendocrine tumors of the stomach, intestines, or pancreas. About 298 adults with tumors that cannot be removed by surgery will receive…
Phase: PHASE2, PHASE3 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New shot aims to cut dangerous COPD attacks
Disease control Recruiting nowThis study tests an experimental drug called CM326, given as a shot, in 318 people with moderate-to-severe COPD. The goal is to see if it can reduce the number of serious flare-ups over 24 to 52 weeks compared to a placebo. Participants must be at least 40 years old, have had COP…
Phase: PHASE2 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a combination of sirolimus (a targeted therapy) with several antibody-drug conjugates (ADCs) in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the combo can shrink tumors. About 444 participants…
Phase: PHASE1, PHASE2 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug cocktail targets Hard-to-Treat stomach cancer
Disease control Recruiting nowThis study tests a combination of two drugs—glumetinib (a targeted therapy) and a special form of docetaxel (chemotherapy)—in people with advanced stomach cancer or other solid tumors that have a specific genetic marker called MET overexpression. The trial has two stages: first t…
Phase: PHASE2 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 15:06 UTC
-
New drug SYH2085 tested in healthy people for first time
Knowledge-focused Recruiting nowThis Phase 1 trial is testing a new drug called SYH2085 in 74 healthy Chinese adults to see if it is safe and how the body processes it. Participants receive either a single dose of SYH2085 or a placebo, and the study also looks at how food affects the drug. This is an early step…
Phase: PHASE1 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC